Extension of phase II therapeutic trial with a humanized non-mitogenic CD3 (ChAgly CD3) [otelixizumab] monoclonal antibody in recently diagnosed type 1 diabetic patients
Phase of Trial: Phase II
Latest Information Update: 12 Jan 2015
At a glance
- Drugs Otelixizumab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 17 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
- 20 Mar 2008 New trial record.